Options are left open as Aceto seeks growth
Executive Summary
Aceto insists that it is plotting a course to return to sales growth, after slumps for its Human Health segment in its financial fourth quarter led to a quarterly loss for the unit.
You may also be interested in...
Aceto Files For Bankruptcy As It Offloads Rising And Chemicals Businesses
Struggling US firm Aceto has filed Chapter 11 bankruptcy petitions at the same time as agreeing to divest its chemicals business assets for US$338 million, with plans to also offload its Rising Pharmaceuticals unit.
AAM Departures Lead To Change Of Chair For IGBA
The AAM has confirmed the departure of three executives, one of whom had also been serving as chair of the IGBA. As a result, the global generics industry association has brought in a new interim chair, at the same time as the head of one of the industry’s largest players has joined its CEO Advisory Committee.
‘In A Word, Complicated’ – AAM’s Burton Talks US Biosimilars
With the first US Humira rival having just hit the market and biosimilars seeing increasing adoption overall, Craig Burton – executive director of the AAM’s Biosimilars Council – tells Generics Bulletin that the US biosimilars market is “doing better, but we still have improvements to make.”